Clinical outcomes of COMBO dual-therapy stents versus contemporary drug- eluting stents: a meta-analysis of randomized trials
This meta-analysis of six randomized trials involving 7,527 patients found that while COMBO dual-therapy stents initially appeared to have higher risks of target lesion failure and mortality compared to contemporary drug-eluting stents, these findings were entirely driven by a single large trial (SORT OUT X), leaving no definitive evidence of a difference in clinical outcomes after sensitivity analysis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, the most common way to open a clogged heart artery has been to slip a tiny metal mesh tube, called a stent, into place. This tube acts as a scaffold, holding the vessel open so blood can flow freely again. Early versions of these tubes were bare metal, but they often led to a frustrating problem: the body's natural healing response would grow too much scar tissue over the metal, narrowing the artery once more. To stop this, engineers developed drug-eluting stents, which slowly release medicine to keep the tissue growth in check. While these drug-coated tubes became the standard of care, they introduced a new worry. Because the medicine stops cell growth, it can also delay the natural healing of the artery's inner lining, leaving the stent exposed to the risk of dangerous blood clots for a longer time.
Scientists have long searched for a way to speed up that healing process without losing the benefits of the medicine. One promising idea was to create a "dual-therapy" stent that not only releases the anti-growth drug but also actively recruits the body's own repair cells to cover the metal surface quickly. This is the concept behind the COMBO stent, a device designed to capture circulating repair cells and help the artery heal itself faster. The big question for doctors and patients has been whether this clever combination actually leads to better outcomes than the best modern drug-coated stents available today. A new analysis of clinical trials set out to find the answer by looking at the hard data from patients who received these devices.
Researchers gathered data from six different randomized trials, which are the gold standard for medical research because they compare treatments directly in a controlled setting. In total, they analyzed the records of 7,527 patients, splitting them into two groups: those who received the COMBO stent and those who received standard drug-eluting stents. The team looked at the most critical outcomes, such as whether the treated artery failed again, if patients needed another procedure, or if they suffered from heart attacks or death. When they first combined all the results, the numbers suggested a troubling trend: patients with the COMBO stent appeared to have a higher risk of these negative events compared to those with standard stents.
However, a closer look at the data revealed that this troubling trend was not a consistent pattern across all patients. The apparent increase in risk was driven almost entirely by one very large study involving thousands of patients, while the other five smaller studies showed no difference between the two types of stents. When the researchers removed that single large study from their calculations, the difference in outcomes vanished completely. The same pattern held true for long-term follow-up data stretching beyond two years. The initial signals of higher risk for the COMBO stent disappeared once the influence of that one dominant trial was set aside. This means that the data does not support the idea that the COMBO stent is inherently worse, nor does it prove that it is better.
The authors of the study suggest that the unique design of the COMBO stent, which includes a slightly thicker metal structure than some newer competitors, might have caused a temporary disadvantage in that one large trial. While the idea of capturing repair cells to speed up healing is sound, the physical design of the stent might have offset those benefits in the short term. The study concludes that we cannot yet say the COMBO stent is superior or inferior to standard options. The evidence remains uncertain, and the apparent risks seen in the initial summary were an artifact of how the data was weighted, not a reflection of a fundamental flaw in the device. To truly understand where this technology fits, more large-scale studies are needed that can compare these devices without being dominated by a single trial. Until then, the medical community must view the COMBO stent as a safe and effective option, but one whose special advantages have not yet been proven to consistently outperform the best modern alternatives.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.